Key Takeaways:
- SpringWorks Therapeutics (SWTX, Financial) is nearing a major acquisition by Merck KGaA valued at approximately $3.5 billion.
- Analysts have set a one-year average price target for SWTX at $72.50, representing a significant upside potential.
- Brokerage firms collectively rate SWTX with a positive "Outperform" status.
SpringWorks Therapeutics (SWTX) experienced a significant surge in its share price following reports that Germany's Merck KGaA is close to acquiring the company for around $3.5 billion. The terms of the deal suggest an acquisition price nearing $47 per share, with potential finalization as soon as Monday, assuming no unforeseen complications arise.
Wall Street Analysts' Price Forecast
According to the projections of eight Wall Street analysts, the one-year average price target for SpringWorks Therapeutics Inc (SWTX, Financial) stands at $72.50. This forecast includes a high prediction of $84.00 and a lower estimate of $63.00, suggesting a notable upside potential of 60.26% from the current trading price of $45.24. Investors seeking more granular forecast data can explore the SpringWorks Therapeutics Inc (SWTX) Forecast page.
Brokerage Recommendations
Based on the consensus from seven prominent brokerage firms, SpringWorks Therapeutics Inc's (SWTX, Financial) average brokerage recommendation is 1.7. This positions the stock within the "Outperform" bracket of the rating scale, which ranges from 1 (Strong Buy) to 5 (Sell). This recommendation reflects a generally positive outlook from the investment community regarding the company's future prospects.
